Committees & Working Groups
PMC’s member working groups are advancing personalized medicine on behalf of institutions from every sector of the health care ecosystem.
Public Policy Committee
Lauren Silvis, J.D.
Michael Sherman, M.D., M.B.A., M.S.
PMC’s Public Policy Committee collaborates to align policy priorities among PMC members and leverage relationships with policymakers to advance legislation and regulations that promote investment in and adoption of personalized medicine.
Science Policy Committee
PMC’s Science Policy Committee collaborates to develop and align medical practices and policies with the evolving base of evidence demonstrating the clinical and economic benefits of personalized medicine.
Six Working Groups
PMC maintains six working groups focused on addressing outstanding opportunities and challenges in personalized medicine.
PMC also convenes ad hoc groups on certain policy issues as they arise.
PMC’s Health Care Working Group provides a forum for the Coalition’s members involved in health care delivery to discuss common challenges and potential solutions for integrating personalized medicine into clinical practice.
PMC’s Health Data Working Group convenes members with expertise and interest in information technology, data, real-world evidence, and privacy issues. The group has helped develop PMC principles encouraging institutions to share data in ways that keep patients engaged as fully informed research partners.
PMC’s Patient Advocacy Organization Working Group provides a forum for the Coalition’s patient advocacy organization members to inform PMC’s policy strategy, align on legislative priorities, and develop shared messages that can empower individual patients to advocate for policies that bring personalized medicine closer to them.
PMC’s Pharmaceutical & Diagnostics Industry Working Group provides a forum for the Coalition’s pharmaceutical and diagnostic industry members to inform PMC’s policy strategy and advocacy activities related to research and development, regulatory oversight, reimbursement, payment reform, and health care quality.
PMC’s Pharmacogenomics (PGx) Working Group convenes members with interest or expertise in issues related to PGx testing. The group guides PMC’s efforts in pharmacogenomics and its related engagements with FDA, clinical guidelines developers, and other stakeholders.
PMC’s Value Assessment Framework Working Group convenes members with interest or expertise in health care value assessment policies and practices. The group discusses challenges and strategies for appropriately accounting for personalized medicine in value and health technology assessments.